8月3日，映恩生物-B盘中下跌5.23%，报172.6港元，成交额2716.64万港元。
消息面上，此前葛兰素史克（GSK）在半年报中大幅提升其B7-H3 ADC管线Ris-Rez的战略优先级，将其定义为2031年后肿瘤业务增长核心，直接冲击映恩生物核心管线DB-1311的竞争格局。该股7月30日已大跌13.7%，当前延续调整态势。此外，市场对基石投资者解禁后的减持压力亦存担忧，叠加公司行权Co-Co模式后需持续投入大量研发资金，资金链压力受到关注。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.